Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in F...((9073) Baxter PI Settlement ...),Health
(9,073)
Baxter PI Settlement 5,700
Non-GAAP Operating Expenses $181,131 $157,664
Non-GAAP Operating income
GAAP Operating Income $70,287 $62,745
Restructuring Costs 6,307 3,518
In-Process Research and Development 9,073
Baxter PI Settlement (5,700)
Non-GAAP Operating income $76,594 $69,636
Non-GAAP Income before taxes
GAAP Income before taxes $77,302 $72,336
Restructuring Costs 6,307 3,518
In-Process Research and Development 9,073
Baxter PI Settlement (5,700)
Non-GAAP Income before taxes $83,609 $79,227
Non-GAAP Net Income
GAAP Net Income $51,980 $49,109
Restructuring Costs 6,307 3,518
In-Process Research and Development 9,073
Baxter PI Settlement (5,700)
Tax benefit associated with Restructuring Costs (2,067) (1,180)
Tax benefit associated with Baxter PI Settlement 1,721
Resolution of Tax Contingencies (3,967)
Non-GAAP NET INCOME $56,220 $52,574
Non-GAAP Net Income per common
share assuming dilution
GAAP Net Income per common share assuming
dilution $1.94 $1.78
Restructuring Costs after tax per common share
'/>"/>
| SOURCE Haemonetics Corporation Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |